Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia
(Open for Feedback on Recommendation until February 19, 2016)

Nivolumab (Opdivo) for Metastatic Melanoma
(Open for Feedback on Recommendation until February 19, 2016)

Ibrutinib (Imbruvica) for Mantle Cell Lymphoma
(Open for Input on Submission until February 12, 2016)

Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma
(Pending Submission as of January 26, 2016)

 

Find a Drug Review